Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary

J Clin Oncol. 2025 Mar 10;43(8):907-911. doi: 10.1200/JCO-24-01802. Epub 2025 Feb 6.

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Publication types

  • Case Reports
  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
  • Humans
  • Immunotherapy* / methods
  • Ipilimumab* / administration & dosage
  • Male
  • Melanoma* / drug therapy
  • Melanoma* / immunology
  • Melanoma* / pathology
  • Melanoma* / secondary
  • Neoplasms, Unknown Primary* / drug therapy
  • Neoplasms, Unknown Primary* / immunology
  • Neoplasms, Unknown Primary* / pathology
  • Nivolumab* / administration & dosage
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • Ipilimumab
  • Nivolumab